News: 2022

Professor Melief to receive 2022 SITC Pedro J. Romero Award

September 08, 2022
Professor Melief to receive 2022 SITC Pedro J. Romero Award
Read more
Professor Melief to receive 2022 SITC Pedro J. Romero Award

MIMETAS appoints Dhaval Patel as Chair of the Board of Directors

September 07, 2022
MIMETAS appoints Dhaval Patel as Chair of the Board of Directors
Read more
MIMETAS appoints Dhaval Patel as Chair of the Board of Directors

ISA Pharmaceuticals' Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer

July 15, 2022
Recognition of commendable, longstanding dedication to the field of cancer immunotherapy
Read more
ISA Pharmaceuticals' Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer

FDA Accepts Byondis' BLA for [Vic-]Trastuzumab Duocarmazine (SYD985) in HER2-Positive Metastatic Breast Cancer

July 12, 2022
Byondis acquired the technology for the development of its anti-HER2 ADC drug from Aglaia's portfolio company Syntarga in 2010.
Read more

In vitro grafting of hepatic spheroids and organoids on a microfluidic vascular bed

June 16, 2022
Scientists from MIMETAS introduce a platform for routine grafting of liver and other tissues on an in vitro grown microvascular...
Read more
In vitro grafting of hepatic spheroids and organoids on a microfluidic vascular bed

Modra Pharmaceuticals Presents In-Depth Data Analysis from Lower Dose Cohort in Phase 2b Study of Oral Taxane ModraDoc006/r in mCRPC Patients at 2022 ASCO Annual Meeting

May 27, 2022
ModraDoc006/r at 20-20/200-100mg dosage eliminated neutropenia and significantly decreased neuropathy while maintaining efficac...
Read more
Modra Pharmaceuticals Presents In-Depth Data Analysis from Lower Dose Cohort in Phase 2b Study of Oral Taxane ModraDoc006/r in mCRPC Patients at 2022 ASCO Annual Meeting

New Data Opens Potential for Patient Stratification for CriPec® Nanomedicines in Cancer and Other Indications via Non- Invasive Imaging

May 04, 2022
Cristal Therapeutics, a Dutch pharmaceutical company developing tailored nanomedicines for the treatment of cancer and other di...
Read more
New Data Opens Potential for Patient Stratification for CriPec® Nanomedicines in Cancer and Other Indications via Non- Invasive Imaging

MIMETAS Expands Adult Stem Cell Organoid License to All Organs

May 03, 2022
MIMETAS, a global leader in Organ-on-a-Chip models and technology, announces today that it has expanded its license to the HUB...
Read more
MIMETAS Expands Adult Stem Cell Organoid License to All Organs

MIMETAS Participates in €325 Million Oncode-PACT Initiative to Accelerate and Improve Oncology Drug Development

April 14, 2022
MIMETAS Participates in €325 Million Oncode-PACT Initiative to Accelerate and Improve Oncology Drug Development
Read more
MIMETAS Participates in €325 Million Oncode-PACT Initiative to Accelerate and Improve Oncology Drug Development

Modra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer, at 2022 ASCO GU Annual Meeting

February 17, 2022
Modra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic...
Read more
Modra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer, at 2022 ASCO GU Annual Meeting

Home > News > Archive

© 2022 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds